无创植入前非整倍体遗传学检测的系统综述
本系统综述旨在探讨无创与微创采样技术用于植入前非整倍体遗传学检测(PGT-A)的效用与准确性;与活检法PGT-A相比总体一致率令人期待,但作者认为在将其作为广泛使用且临床效用强的工具前,仍需更多研究与理解。
要点
- 无创与微创PGT-A采样来源包括胚胎培养液与囊胚腔液,旨在避免胚胎活检。
- 与活检法PGT-A相比,总体一致率令人期待。
- 作者认为采纳无创与微创PGT-A为广泛使用工具前仍需更多研究与理解。
核心结论
- 与活检法PGT-A相比总体一致率令人期待,但作者认为在将无创与微创PGT-A作为广泛使用且临床效用强的工具前,仍需更多研究与理解。
研究设计与样本
- 系统综述,探索当前可用的关于无创与微创采样技术用于PGT-A的研究。
主要发现
- 与活检法PGT-A相比,总体一致率令人期待。
临床怎么用
- 作者认为在将无创与微创PGT-A作为广泛使用且临床效用强的工具前,仍需更多研究与理解。
局限性
- 作者指出在将无创与微创PGT-A作为广泛使用且临床效用强的工具前,仍需更多研究与理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Noninvasive and minimally invasive preimplantation genetic testing for aneuploidy (PGT-A) is a tool that may one day become the gold standard for embryonic chromosomal screening. Investigations on this topic have ranged from studying the culture media of embryos to the fluid inside the blastocoel, all in an attempt to find a reliable source of DNA without the need to biopsy the embryo. There is great interest across the board, both from those for and against biopsy, in a reliable test process that would give the patient and provider the same information possible from a biopsy without the risk. We aim to explore the current available research to better understand the utility and accuracy of PGT-A with these new sampling techniques. General concordance rates in comparison with biopsy-based PGT-A are promising, but it is clear that additional research and understanding are needed before adopting noninvasive and minimally invasive PGT-A as a widely used tool with strong clinical utility.
引用
- Cinnioglu C, Glessner H, Jordan A, et al. A systematic review of noninvasive preimplantation genetic testing for aneuploidy. Fertil Steril. 2023. PMID: 37356468. doi:10.1016/j.fertnstert.2023.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。